Abstract
Prostate cancer is the most common non-cutaneous cancer among men in the United States. Most will be diagnosed at an early stage, but a significant number will still develop metastatic castration resistant disease. Docetaxel has demonstrated improved quality of life and overall survival in metastatic castration-resistant prostate cancer but virtually all patients will ultimately become refractory to taxane therapy. Second-line options are limited and new effective chemotherapeutic agents or combinations are needed in this setting. This review will focus on cytotoxic compounds in clinical investigation either in combination with taxanes in the first or second-line setting and other novel compounds, such as platinums and microtubule-targeting agents that are in active clinical investigation.
Keywords: Chemotherapy, platinum, docetaxel, microtubule-targeting agents, epothilones, prostate cancer
Anti-Cancer Agents in Medicinal Chemistry
Title: Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer
Volume: 9 Issue: 10
Author(s): Patrick Lee and Jeanny B. Aragon-Ching
Affiliation:
Keywords: Chemotherapy, platinum, docetaxel, microtubule-targeting agents, epothilones, prostate cancer
Abstract: Prostate cancer is the most common non-cutaneous cancer among men in the United States. Most will be diagnosed at an early stage, but a significant number will still develop metastatic castration resistant disease. Docetaxel has demonstrated improved quality of life and overall survival in metastatic castration-resistant prostate cancer but virtually all patients will ultimately become refractory to taxane therapy. Second-line options are limited and new effective chemotherapeutic agents or combinations are needed in this setting. This review will focus on cytotoxic compounds in clinical investigation either in combination with taxanes in the first or second-line setting and other novel compounds, such as platinums and microtubule-targeting agents that are in active clinical investigation.
Export Options
About this article
Cite this article as:
Lee Patrick and Aragon-Ching B. Jeanny, Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/187152009789734991
DOI https://dx.doi.org/10.2174/187152009789734991 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Strategies for Treatment of Inflammation-related Depression
Current Neuropharmacology Performance and Effect of Automatic Contouring in Automatic Adaptive Planning for Prostate Cancer Volumetric Modulated Radiotherapy
Recent Patents and Topics on Imaging (Discontinued) Diabetic Patients with Psychiatric Illness
Current Diabetes Reviews Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
Current Cancer Drug Targets Cytokines as a Precipitant of Depressive Illness: Animal and Human Studies
Current Pharmaceutical Design Labeling Strategies of Peptides with 18F for Positron Emission Tomography
Current Topics in Medicinal Chemistry Analytical and Pharmacological Aspects of Therapeutic Drug Monitoring of mTOR Inhibitors
Current Drug Metabolism Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry A Novel Class of Emerging Anticancer Compounds: Oxyprenylated Secondary Metabolites from Plants and Fungi
Current Medicinal Chemistry Genetics of Obesity: What have we Learned?
Current Genomics Novel Subtype Specific and Universal Somatostatin Analogues: Clinical Potential and Pitfalls
Current Pharmaceutical Design Novel Strategies and Model Studies for Colon Targeted Drug Delivery
Drug Delivery Letters Inflammasome, Inflammation and Cancer: An Interrelated Pathobiological Triad
Current Drug Targets Hypothetical Role of Growth Factors to Reduce Intervertebral Disc Degeneration Significantly through Trained Biological Transformations
Current Pharmaceutical Design Privileged 1,2,4-Oxadiazoles in Anticancer Drug Design: Novel 5- Aryloxymethyl-1,2,4-oxadiazole Leads for Prostate Cancer Therapy
Letters in Drug Design & Discovery Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Topics in Medicinal Chemistry Editorial [Hot topic: Current Topics in the Development of Radioligands for Positron-Emission Tomography Imaging (Guest Editors: Andrew G. Horti and Robert F. Dannals)]
Current Topics in Medicinal Chemistry The Hormetic Role of Dietary Antioxidants in Free Radical-Related Diseases
Current Pharmaceutical Design